{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T20:14:29Z","timestamp":1776888869056,"version":"3.51.2"},"reference-count":63,"publisher":"Society of Nuclear Medicine","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.2967\/jnumed.121.262324","type":"journal-article","created":{"date-parts":[[2021,8,19]],"date-time":"2021-08-19T18:12:18Z","timestamp":1629396738000},"page":"543-548","source":"Crossref","is-referenced-by-count":3,"title":["PET-Based Staging Is Cost-Effective in Early-Stage Follicular Lymphoma"],"prefix":"10.2967","volume":"63","author":[{"given":"Andrea C.","family":"Lo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lyndon P.","family":"James","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anca","family":"Prica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Raymakers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart","family":"Peacock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melody","family":"Qu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex V.","family":"Louie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerry J.","family":"Savage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurie H.","family":"Sehn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Hodgson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna C.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans T.T.","family":"Eich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Wirth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.G. Myriam","family":"Hunink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1602","published-online":{"date-parts":[[2021,8,19]]},"reference":[{"key":"2022042908200978000_63.4.543.1","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1200\/JCO.1996.14.4.1282","article-title":"Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University","volume":"14","author":"Mac Manus","year":"1996","journal-title":"J Clin Oncol."},{"key":"2022042908200978000_63.4.543.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(01)01747-3"},{"key":"2022042908200978000_63.4.543.3","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1182\/blood.2019004588","article-title":"Long-term outcomes for patients with limited-stage follicular lymphoma: update of a population-based study","volume":"136","author":"Lo","year":"2020","journal-title":"Blood."},{"key":"2022042908200978000_63.4.543.4","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw400"},{"key":"2022042908200978000_63.4.543.5","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s00066-020-01624-w","article-title":"Oncological outcome and recurrence pattern analysis after involved-field irradiation in combination with rituximab for early-stage nodal and extranodal follicular lymphoma","volume":"196","author":"K\u00f6nig","year":"2020","journal-title":"Strahlenther Onkol."},{"key":"2022042908200978000_63.4.543.6","doi-asserted-by":"crossref","first-page":"10069","DOI":"10.1038\/s41598-021-89316-y","article-title":"A comprehensive retrospective cohort study of the journey of B-cell lymphoma in Taiwan","volume":"11","author":"Pei","year":"2021","journal-title":"Sci Rep."},{"key":"2022042908200978000_63.4.543.7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-04-843540"},{"key":"2022042908200978000_63.4.543.8","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s00259-018-4112-2","article-title":"Outcome of patients with early-stage follicular lymphoma staged with 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) and treated with radiotherapy alone","volume":"46","author":"Ng","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2022042908200978000_63.4.543.9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"2022042908200978000_63.4.543.10","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/RCT.0000000000000485","article-title":"Systematic review on the additional value of 18F-fluoro-2-deoxy-D-glucose positron emission tomography in staging follicular lymphoma","volume":"41","author":"Adams","year":"2017","journal-title":"J Comput Assist Tomogr."},{"key":"2022042908200978000_63.4.543.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1405158"},{"key":"2022042908200978000_63.4.543.12","unstructured":"Guidelines for the Economic Evaluation of Health Technologies : Canada. 4th ed. Canadian Agency for Drugs and Technologies in Health; 2017:1\u201376."},{"key":"2022042908200978000_63.4.543.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2007.09.051"},{"key":"2022042908200978000_63.4.543.14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.1495"},{"key":"2022042908200978000_63.4.543.15","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.ijrobp.2019.03.004","article-title":"Salvage treatment and survival for relapsed follicular lymphoma following primary radiation therapy: a collaborative study on behalf of ILROG","volume":"104","author":"Binkley","year":"2019","journal-title":"Int J Radiat Oncol Biol."},{"key":"2022042908200978000_63.4.543.16","doi-asserted-by":"crossref","first-page":"e0131158","DOI":"10.1371\/journal.pone.0131158","article-title":"Radiotherapy compared to other strategies in the treatment of stage I\/II follicular lymphoma: a study of 404 patients with a median follow-pp of 15 years","volume":"10","author":"Barzenje","year":"2015","journal-title":"PLoS One."},{"key":"2022042908200978000_63.4.543.17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14110-4"},{"key":"2022042908200978000_63.4.543.18","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70027-0"},{"key":"2022042908200978000_63.4.543.19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61763-2"},{"key":"2022042908200978000_63.4.543.20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.5827"},{"key":"2022042908200978000_63.4.543.21","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62175-7"},{"key":"2022042908200978000_63.4.543.22","unstructured":"Data tables in PDF and TXT format. Statistics Canada website. https:\/\/www150.statcan.gc.ca\/n1\/pub\/84-537-x\/4064441-eng.htm. Modified July 31, 2006. Accessed January 6, 2022."},{"key":"2022042908200978000_63.4.543.23","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1002\/cncr.29372","article-title":"Frontline rituximab monotherapy induction versus a watch and wait approach for asymptomatic advanced-stage follicular lymphoma: a cost-effectiveness analysis","volume":"121","author":"Prica","year":"2015","journal-title":"Cancer."},{"key":"2022042908200978000_63.4.543.24","doi-asserted-by":"crossref","first-page":"e0131158","DOI":"10.1371\/journal.pone.0131158","article-title":"Radiotherapy compared to other strategies in the treatment of stage I\/II follicular lymphoma: a study of 404 patients with a median follow-up of 15 years","volume":"10","author":"Barzenje","year":"2015","journal-title":"PLoS ONE."},{"key":"2022042908200978000_63.4.543.25","doi-asserted-by":"crossref","first-page":"A449","DOI":"10.1016\/j.jval.2017.08.286","article-title":"UK utility elicitation in patients with follicular lymphoma [abstract]","volume":"20","author":"Wang","year":"2017","journal-title":"Value Health."},{"key":"2022042908200978000_63.4.543.26","doi-asserted-by":"crossref","first-page":"A294","DOI":"10.1016\/S1098-3015(10)63491-2","article-title":"PCN62 utility elicitation of patients with follicular lymphoma [abstract]","volume":"9","author":"Wild","year":"2006","journal-title":"Value Health."},{"key":"2022042908200978000_63.4.543.27","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70036-1"},{"key":"2022042908200978000_63.4.543.28","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1016\/j.jval.2018.03.007","article-title":"A generic model for follicular lymphoma: predicting cost, life expectancy, and quality-adjusted-life-year using UK population\u2013based observational data","volume":"21","author":"Wang","year":"2018","journal-title":"Value Health."},{"key":"2022042908200978000_63.4.543.29","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2165\/00019053-200927010-00006","article-title":"Cost effectiveness of high-dose chemotherapy with autologous stem cell support as initial treatment of aggressive non-Hodgkin\u2019s lymphoma","volume":"27","author":"Fagnoni","year":"2009","journal-title":"Pharmacoeconomics."},{"key":"2022042908200978000_63.4.543.30","doi-asserted-by":"crossref","first-page":"e228","DOI":"10.3747\/co.23.2998","article-title":"Estimating the costs of intensity-modulated and 3-dimensional conformal radiotherapy in Ontario","volume":"23","author":"Yong","year":"2016","journal-title":"Curr Oncol."},{"key":"2022042908200978000_63.4.543.31","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.carj.2017.08.001","article-title":"Incidence and economic impact of incidental findings on 18F-FDG PET\/CT imaging","volume":"69","author":"Adams","year":"2018","journal-title":"Can Assoc Radiol J."},{"key":"2022042908200978000_63.4.543.32","unstructured":"Schedule of benefits: physician services under the Health Insurance Act. Ontario Ministry of Health and Long-Term Care website. https:\/\/www.health.gov.on.ca\/en\/pro\/programs\/ohip\/sob\/physserv\/sob_master.pdf. Published July 2, 2021. Accessed January 6, 2022."},{"key":"2022042908200978000_63.4.543.33","doi-asserted-by":"crossref","first-page":"18","DOI":"10.2174\/1876824501204010018","article-title":"Economic analysis of alemtuzumab (MabCampath\u00ae) in fludarabinerefractory chronic lymphocytic leukemia","volume":"4","author":"Mittmann","year":"2012","journal-title":"Open Pharmacoecon Health Econ J."},{"key":"2022042908200978000_63.4.543.34","unstructured":"RiTUXimab. Cancer Care Ontario website. https:\/\/www.cancercareontario.ca\/en\/drugformulary\/drugs\/riTUXimab. Published 2020. Accessed January 6, 2022."},{"key":"2022042908200978000_63.4.543.35","unstructured":"Schedule of benefits for laboratory services. Ontario Ministry of Health and Long-Term Care website. http:\/\/www.health.gov.on.ca\/en\/pro\/programs\/ohip\/sob\/lab\/lab_mn2020.pdf. Published July 1, 2020. Accessed January 6, 2022."},{"key":"2022042908200978000_63.4.543.36","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24773"},{"key":"2022042908200978000_63.4.543.37","unstructured":"Treanda for non-Hodgkin lymphoma. Canadian Agency for Drugs and Technologies in Health website. https:\/\/cadth.ca\/treanda-indolent-non-hodgkin-lymphoma. Updated December 14, 2012. Accessed January 6, 2022."},{"key":"2022042908200978000_63.4.543.38","first-page":"719","article-title":"The cost of treating relapsed indolent non-Hodgkin\u2019s lymphoma in an international setting: retrospective analysis of resource use","volume":"87","author":"Herold","year":"2002","journal-title":"Haematologica."},{"key":"2022042908200978000_63.4.543.39","doi-asserted-by":"publisher","DOI":"10.1177\/0269216309346546"},{"key":"2022042908200978000_63.4.543.40","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1002\/cncr.30672","article-title":"[18F]-FDG PET\/CT in the staging and management of indolent lymphoma: a prospective multicenter PET registry study","volume":"123","author":"Metser","year":"2017","journal-title":"Cancer."},{"key":"2022042908200978000_63.4.543.41","doi-asserted-by":"publisher","DOI":"10.1007\/s11307-009-0200-9"},{"key":"2022042908200978000_63.4.543.42","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22807"},{"key":"2022042908200978000_63.4.543.43","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s00259-018-4112-2","article-title":"Outcome of patients with early-stage follicular lymphoma staged with 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) and treated with radiotherapy alone","volume":"46","author":"Ng","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2022042908200978000_63.4.543.44","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/RCT.0000000000000485","article-title":"Systematic review on the additional value of 18F-fluoro-2-deoxy-D-glucose positron emission tomography in staging follicular lymphoma","volume":"41","author":"Adams","year":"2017","journal-title":"J Comput Assist Tomogr."},{"key":"2022042908200978000_63.4.543.45","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-09-2778"},{"key":"2022042908200978000_63.4.543.46","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl014"},{"key":"2022042908200978000_63.4.543.47","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08969.x"},{"key":"2022042908200978000_63.4.543.48","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-010-1539-5"},{"key":"2022042908200978000_63.4.543.49","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt137"},{"key":"2022042908200978000_63.4.543.50","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3816\/CLM.2008.n.040","article-title":"Value of [18F]fluorodeoxyglucose positron emission tomography in the management of follicular lymphoma: the end of a dilemma?","volume":"8","author":"Janikova","year":"2011","journal-title":"Clin Lymphoma & Myeloma."},{"key":"2022042908200978000_63.4.543.51","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp030"},{"key":"2022042908200978000_63.4.543.52","unstructured":"Non-Hodgkin\u2019s lymphoma: diagnosis and management. National Institute for Health and Care Excellence website. https:\/\/www.nice.org.uk\/guidance\/ng52. Published July 20, 2016. Accessed January 6, 2022."},{"key":"2022042908200978000_63.4.543.53","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/ajh.24937","article-title":"Follicular lymphoma: 2018 update on diagnosis and management","volume":"93","author":"Freedman","year":"2018","journal-title":"Am J Hematol."},{"key":"2022042908200978000_63.4.543.54","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.084723"},{"key":"2022042908200978000_63.4.543.55","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2008.n.020"},{"key":"2022042908200978000_63.4.543.56","first-page":"1422","article-title":"Cost analysis of common treatment options for indolent follicular non-Hodgkin\u2019s lymphoma","volume":"90","author":"van Agthoven","year":"2005","journal-title":"Haematologica."},{"key":"2022042908200978000_63.4.543.57","doi-asserted-by":"publisher","DOI":"10.1080\/02841860802120028"},{"key":"2022042908200978000_63.4.543.58","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2009.00676.x"},{"key":"2022042908200978000_63.4.543.59","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2165\/11314070-000000000-00000","article-title":"Cost effectiveness of rituximab maintenance therapy in follicular lymphoma","volume":"28","author":"Deconinck","year":"2010","journal-title":"Pharmacoeconomics."},{"key":"2022042908200978000_63.4.543.60","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2012.02.019"},{"key":"2022042908200978000_63.4.543.61","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jval.2014.12.017","article-title":"Comparing the cost-effectiveness of rituximab maintenance and radioimmunotherapy consolidation versus observation following first-line therapy in patients with follicular lymphoma","volume":"18","author":"Chen","year":"2015","journal-title":"Value Health."},{"key":"2022042908200978000_63.4.543.62","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.3260"},{"key":"2022042908200978000_63.4.543.63","doi-asserted-by":"crossref","first-page":"e359","DOI":"10.1016\/S2352-3026(18)30090-5","article-title":"Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis","volume":"5","author":"Federico","year":"2018","journal-title":"Lancet Haematol."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.121.262324","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T15:22:35Z","timestamp":1651245755000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.121.262324"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,19]]},"references-count":63,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,3,31]]},"published-print":{"date-parts":[[2022,4]]}},"alternative-id":["10.2967\/jnumed.121.262324"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.121.262324","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,19]]}}}